Li Yunxia, Jiang Xuehua, Lan Ke, Jiang Qian
West China School of Pharmacy, Sichuan University, 610041, Sichuan, China.
Eur J Drug Metab Pharmacokinet. 2009 Jul-Sep;34(3-4):221-7. doi: 10.1007/BF03191177.
The objective of this study was to determine and compare the plasma concentrations of rosuvastatin following single- and multiple-dose administration in Chinese volunteers. The study was of an open label, randomized, three-way cross-over design and was conducted in 12 subjects. Single dose administration of the rosuvastatinon was characterized by a rapid absorption (2.045 +/- 0.891 h, 2.273 +/- 1.009 h and 1.667 +/- 0.651 h) and a marked peak plasma concentration (9.938 +/- 4.438, 28.09 +/- 12.075 and 43.092 +/- 22.09 ng/ml) for the three different doses (5 mg, 10 mg and 20 mg) of rosuvastatin. The apparent elimination half-life amounted to 7.914 +/- 3.813 h, 8.445 +/- 4.994 h and 15.401 +/- 5.429 h following administration, respectively. Similar findings were obtained after multiple dosing. A rapid absorption (3 +/- 1.365 h, 3.042 +/- 1.054 h and 2.375 +/- 0.829 h) and a marked peak plasma concentration (9.288 +/- 5.314, 18.808 +/- 6.687 and 49.808 +/- 23.516 ng/ml) for the three different doses (5 mg, 10 mg and 20 mg) of rosuvastatin were observed. The apparent elimination half-life amounted to 13.181 +/- 5.492 h, 8.035 +/- 3.331 h and 15.509 +/- 6.43 h following administration, respectively. Small differences in gender are not considered clinically relevant, and dose adjustments based on gender are not anticipated. But the state of fed or fasting will affect the pharmacokinetic of rosuvastatin.
本研究的目的是测定并比较瑞舒伐他汀在中国志愿者单剂量和多剂量给药后的血浆浓度。该研究采用开放标签、随机、三交叉设计,共纳入12名受试者。单剂量服用瑞舒伐他汀时,三种不同剂量(5毫克、10毫克和20毫克)的瑞舒伐他汀均呈现快速吸收(分别为2.045±0.891小时、2.273±1.009小时和1.667±0.651小时)和显著的血浆峰浓度(分别为9.938±4.438、28.09±12.075和43.092±22.09纳克/毫升)。给药后表观消除半衰期分别为7.914±3.813小时、8.445±4.994小时和15.401±5.429小时。多次给药后也得到了类似的结果。观察到三种不同剂量(5毫克、10毫克和20毫克)的瑞舒伐他汀呈现快速吸收(分别为3±1.365小时、3.042±1.054小时和2.375±0.829小时)和显著的血浆峰浓度(分别为9.288±5.314、18.808±6.687和49.808±23.516纳克/毫升)。给药后表观消除半衰期分别为13.181±5.492小时、8.035±3.331小时和15.509±6.43小时。性别上的微小差异在临床上不被认为具有相关性,预计也无需根据性别调整剂量。但是进食或禁食状态会影响瑞舒伐他汀的药代动力学。